OTTAWA, March 30 /CNW/ – The following is a statement by Russell Williams, President of Canada’s Research-Based Pharmaceutical Companies (Rx&D) responding to the Government of Canada announcement of an agreement to supply influenza vaccine.
“As the industry that develops the medicines and vaccines that improve and save lives, we commend the Government of Canada and Health Minister Leona Aglukkaq for reaching agreements for the supply of influenza vaccines to prevent infectious disease and protect public health.
“These agreements will be instrumental in ensuring that governments and public health officials in Canada can respond quickly, appropriately and in a cost effective way to protect Canadians from outbreaks of the pandemic and seasonal flu.
“The agreements are with GlaxoSmithKline Inc. as the primary supplier of pandemic flu vaccine and with Sanofi Pasteur Limited as an additional supplier for vulnerable populations. GlaxoSmithKline Inc., Sanofi Pasteur Limited., and Novartis Pharmaceuticals Canada Inc. will provide provinces and territories with vaccines for their annual flu immunization programs.
[Note from SaneVax: Please note the subtle reference to pandemic flu. Are we already gearing up for yet another quasi-pandemic this year? Is fear the only way pharmaceutical companies can get consumers to purchase their product? What happened to advertising health benefits and efficacy? Perhaps the scientific studies conducted around the world showing little to no benefit post-flu vaccination have made their way to medical consumers. Maybe next year governments will read the studies, too.]